- Global Pharma News & Resources

Rising point-of-care D-dimer testing demand will boost the d-dimer testing market, forecast to touch US$ 1.6 Billion by 2026 at a CAGR of 5%

Noida, Uttar Pradesh, India, February 26 2021 (Wiredrelease) Report Ocean Pvt Ltd –:Global D-Dimer Testing Market is estimated to see healthy growth, pegged at a CAGR of ~5% during the forecast period 2020-2026. A rapid change in demand pattern for next-generation point-of-care D-dimer testing has primarily driven the market. This is due to implementing POC solutions significantly to minimize patient stay length, reduce waiting time, enable faster diagnosis, and improve the patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost D-dimer testing growth. A rise in the incidence rate of Venous Thromboembolism (VTE) coupled with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation increases the demand for D-dimer testing.

Download Detailed COVID-19 Impact Sample Report at @

The effects of heterophilic antibodies on the D-dimer level estimation remain a significant challenge in the clinical examination of cardiac and other diseases. This results in substantial differences in the results. Studies suggest that the combination of instrumental methods, incorporation of heterophilic antibody blockers along with clinical performance, and imaging data can rule out this interference, thus pronouncing the need for further research in this sector.

Point-of-care D-dimer Testing witness high growth throughout the forecast period 

In terms of accurate quantitative valuation of D-dimer, laboratory-based analysis is a robust technique compared to the point-of-care test. Moreover, the laboratory-based test can be paramount in identifying individuals at risk of a first thrombotic event and detecting the chances of having a recurrent VTE. Overall, the drawbacks of laboratory tests include the need for adequate space to set up and high response time (40 minutes to 50 minutes) compared to POC tests (10 minutes to 15 minutes). Moreover, the clinical laboratory test is commonly used to determine D-dimer levels in blood serum in a laboratory setup. Compared to coagulation analyzers, the demand for clinical chemistry analyzers is high due to the test’s low cost. Technological advancements have contributed significantly to reducing the unit cost associated with D-dimer tests at laboratories and POCs. The advent of sensitive D-dimer assays used on automated coagulation analyzers has wholly revolutionized the market dynamics in the past few years. Kits used in coagulation analyzers are particular to the device/manufacturer and are expensive compared to clinical chemistry analyzers.

Segmentation Overview of the Global D-Dimer Testing Market

The d-dimer testing market is segmented into Product, Test Type, Method, and End-use. These major market segments are further categorized into various sub-segments to study the market in detail.

By Product Outlook (Analyzers, Reagents & Consumables)

By Test Type Outlook (Clinical Laboratory Tests, Point-of-Care Tests)

By Method Outlook (Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, Others)

By End-use Outlook (Hospitals, Academic & Research Institutes, Diagnostic Centers, Others)

Key Players Insights

Abbott Laboratories, F. Hoffman-La Roche, Beckman Coulter, Alere, Bio/Data, Becton Dickinson, Sysmex, Siemens Healthcare, Trinity Biotech, and Thermo Fisher Scientific, among others, are some significant players included in the research study of the global d-dimer testing market.

To Get the Sample Copy of Report Visit @

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 26-Feb-2021